Skip to content

H.R. 1117 · 119th Congress (2025–2027)

Responsibility in Drug Advertising Act of 2025

This bill prohibits direct-to-consumer advertising of new drugs during the first three years following their approval by the Food and Drug Administration (FDA). Direct-to-consumer advertising includes advertising via social media.

Upon request from a drug’s sponsor, the FDA may waive the prohibition during the third year following a drug’s approval if it determines that the direct-to-consumer advertising of the drug would have an affirmative value to public health. Conversely, the FDA may prohibit such advertising beyond the three-year period following approval if it determines that the drug has significant adverse health effects based on post-approval studies, adverse event reports, and other appropriate resources.

The prohibition applies to new drugs approved beginning one year before the bill’s enactment.

Show official title

To amend the Federal Food, Drug, and Cosmetic Act to restrict direct-to-consumer drug advertising.

Referred to committee

Latest actionReferred to committee

This bill’s path

This is H.R. 1117’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

Sponsor
Rep. Rosa L. DeLauro (D-CT-3)
Policy area
Health
Subjects
  • Broadcasting, cable, digital technologies
  • Drug safety, medical device, and laboratory regulation
  • Internet, web applications, social media
  • Marketing and advertising
  • Prescription drugs

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest

    Referred to committee

    Referred to the House Committee on Energy and Commerce.

    Sources

Committees

  1. HouseEnergy and CommerceReferred Feb 7, 2025

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (2)
  1. Responsibility in Drug Advertising Act of 2025

    Display title, Short title · Introduced in House

  2. To amend the Federal Food, Drug, and Cosmetic Act to restrict direct-to-consumer drug advertising.

    Official title · Introduced in House